TRUM.F Stock Overview
Engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Terumo Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥21.09 |
| 52 Week High | JP¥22.26 |
| 52 Week Low | JP¥15.00 |
| Beta | 0.41 |
| 11 Month Change | 5.65% |
| 3 Month Change | 8.25% |
| 1 Year Change | 36.39% |
| 33 Year Change | -1.50% |
| 5 Year Change | 21.37% |
| Change since IPO | 152.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRUM.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 14.2% | 1.2% | 3.9% |
| 1Y | 36.4% | 27.0% | 33.2% |
Return vs Industry: TRUM.F exceeded the US Medical Equipment industry which returned 27% over the past year.
Return vs Market: TRUM.F exceeded the US Market which returned 33.2% over the past year.
Price Volatility
| TRUM.F volatility | |
|---|---|
| TRUM.F Average Weekly Movement | 17.1% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRUM.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TRUM.F's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1921 | n/a | Hikaru Samejima | www.terumo.com |
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts.
Terumo Corporation Fundamentals Summary
| TRUM.F fundamental statistics | |
|---|---|
| Market cap | US$28.79b |
| Earnings (TTM) | US$767.94m |
| Revenue (TTM) | US$6.34b |
37.5x
P/E Ratio4.5x
P/S RatioIs TRUM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRUM.F income statement (TTM) | |
|---|---|
| Revenue | JP¥986.67b |
| Cost of Revenue | JP¥456.87b |
| Gross Profit | JP¥529.80b |
| Other Expenses | JP¥410.32b |
| Earnings | JP¥119.49b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 80.70 |
| Gross Margin | 53.70% |
| Net Profit Margin | 12.11% |
| Debt/Equity Ratio | 13.3% |
How did TRUM.F perform over the long term?
See historical performance and comparison